latest news releases from the newsroom
Propalms, Inc. Continues With Uplisting Process by Filing Form 10QSB Quarterly Report
MALTON, England, June 17, 2008 (PRIME NEWSWIRE) -- Propalms, Inc. (Pink Sheets:PRPM) is pleased to announce that the Company has filed Form 10QSB with the Securities and Exchange Commission, reporting its First Quarter 2008 financial statements. Propalms' reported revenue for the First Quarter of 2008 of $256,167. By filing its' Form 10QSB, Propalms continues to move forward with their plans to uplist to the Over-The-Counter Bulletin Board.
Genesis Lease Ltd.
Genesis Secures 11-Year A320-200 Financing
SHANNON, Ireland, June 17, 2008 (PRIME NEWSWIRE) -- Genesis Lease Limited (NYSE:GLS) today announced that it has secured long-term bank debt from KfW IPEX-Bank in Germany to finance an Airbus A320-200 aircraft leased to Deccan Aviation Limited ('Deccan') of Bangalore, India until 2019.
Flushing Financial Corporation
Flushing Financial to Present At Fox-Pitt Kelton Conference On June 18, 2008
LAKE SUCCESS, NY, June 17, 2008 (PRIME NEWSWIRE) -- Flushing Financial Corporation (Nasdaq:FFIC), the parent holding company for Flushing Savings Bank, FSB, today announced that John R. Buran, Flushing Financial's President and Chief Executive Officer, and David W. Fry, Flushing Financial's Executive Vice President and Chief Financial Officer, will participate in the Fox-Pitt Kelton Small & Mid-Cap Bank and Insurance Conference on June 18, 2008 in New York City.
Aastrom Biosciences, Inc.
Aastrom to Initiate Phase II Clinical Trial Using Cardiac Repair Cells Derived From Patient's Own Bone Marrow for Treatment of Severe Chronic Heart Failure
ANN ARBOR, Mich., June 17, 2008 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced plans to initiate a 40 patient U.S. Phase II clinical trial to study the use of Cardiac Repair Cells (CRCs), a mixture of stem and progenitor cells derived from a patient's own bone marrow, for the treatment of dilated cardiomyopathy (DCM), a severe form of chronic heart failure. Aastrom is now authorized under U.S. Food & Drug Administration (FDA) regulations to initiate its first Investigational New Drug (IND) clinical trial for cardiac regeneration. CRCs, manufactured using Aastrom's Tissue Repair Cell (TRC) technology, previously received Orphan Drug Designation from the FDA for the treatment of DCM.
JetBlue Airways Corporation
JetBlue Airways Ranked 'Highest in Customer Satisfaction Among Low Cost Carriers in North America' by J.D. Power and Associates
NEW YORK, June 17, 2008 (PRIME NEWSWIRE) -- JetBlue Airways (Nasdaq:JBLU) today was awarded highest honors in airline customer satisfaction among low-cost carriers for the third year in a row by J.D. Power and Associates 2008 North America Airline Satisfaction Study(SM). This is the fourth consecutive customer satisfaction award JetBlue has received from J.D. Power and Associates. The airline, based in New York, ranked highest in satisfaction among low-cost airlines in 2007 and 2006, and among all U.S. major airlines in 2005.